FDA Approves Landmark Sickle Cell Gene Therapies, Casgevy and Lyfgenia

FRIDAY, Dec. 8, 2023 -- The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that uses gene-editing technology. Casgevy, developed by Vertex...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news